CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 43 enrolled
Drug / intervention
Glargine insulindrug
Likely dose
Glargine insulin 180 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01203774
NCT01203774Phase 4Completed
CompareCT.gov

"Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients Discharged From the Hospital"

University of Colorado, Denver·interventional·Posted Sep 16, 2010·Updated Aug 6, 2021

In Brief

A Phase 4 clinical trial evaluating Glargine insulin for Diabetes. Completed, enrolled 43 participants across 1 site.

Detailed Summary

In this study the investigators would like to test the hypothesis that in diabetic patients discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected Glargine in terms of diabetes control, compliance, and patient satisfaction and preference. The investigators will test this hypothesis in a randomized, crossover trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
CollaboratorsSanofi

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 16, 2010
Enrollment StartSep 1, 2010
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.8 years ago

Interventions

Glargine insulindrug

20-180 units per day